Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments.

Drugs - 1 May 2024

Torres-Jiménez Javier, Espinar Javier Baena, de Cabo Helena Bote, Berjaga María Zurera, Esteban-Villarrubia Jorge, Fraile Jon Zugazagoitia, Paz-Ares Luis

Abstract excerpt

Among the most common molecular alterations detected in non-small-cell lung cancer (NSCLC) are mutations in Kristen Rat Sarcoma viral oncogene homolog (KRAS). KRAS mutant NSCLC is a heterogenous group of diseases, different from other oncogene-driven tumors in terms of biology and response to therapies. Despite efforts to develop drugs aimed at inhibiting KRAS or its signaling pathways, KRAS had remained...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Piperazines

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyridines

Share to Pyrimidines

Source

Identifiers

PMID: 38625662
DOI: 10.1007/s40265-024-02030-7

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments.PMID 38625662Read ↗

Current perspectives of KRAS in non-small cell lung cancer.Semantic proximity Read ↗

KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies.Semantic proximity Read ↗

Targeting KRAS G12C in non-small cell lung cancer: Breakthrough inhibitors and combination approaches.Semantic proximity Read ↗

Advances in targeting KRAS mutations: A promising approach for the treatment of non‑small cell lung cancer (Review).Semantic proximity Read ↗

KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing.Semantic proximity Read ↗

Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic StrategiesSemantic proximity Read ↗

KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges.Semantic proximity Read ↗

Targeting KRASG12D mutation in non-small cell lung cancer: molecular mechanisms and therapeutic potential.Semantic proximity Read ↗

On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma.Semantic proximity Read ↗

Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.Semantic proximity Read ↗

Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.Semantic proximity Read ↗

From bench to bedside: current development and emerging trend of KRAS-targeted therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.